Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Key Takeaways

Humanin is a small mitochondria-derived protein first reported in 2001 for its ability to protect neurons from Alzheimer’s-related stress. Since then, it has been recognized as part of a larger family of mitochondrial microproteins that promote survival under cellular stress. Research shows Humanin supports brain, heart, vascular, and pancreatic health by regulating metabolism, lowering inflammation, preventing apoptosis, and strengthening resilience against age-related decline. Levels decrease with age and are often lower in chronic illness, while higher levels are associated with longevity. Because of these broad benefits, Humanin is being studied as a potential therapeutic tool to improve healthspan.

What Is Humanin?

Humanin (HN) is a 24–amino acid peptide encoded in the mitochondrial 16S rRNA gene (MT-RNR2). First identified as a neuroprotective “rescue factor,” it prevents neuronal death from Alzheimer’s disease–related insults. Subsequent work established HN as a model for mitochondrial-derived peptides with wide-ranging protective effects. HN acts both inside cells and as a secreted signal, blocking pro-apoptotic proteins and activating pro-survival pathways. Potent analogues such as S14G-humanin (HNG) expand its activity. Across diverse models, HN safeguards neurons, pancreatic β-cells, cardiomyocytes, and endothelial cells, improves function in Alzheimer’s, atherosclerosis, diabetes, and aging, and even extends lifespan in C. elegans.

Genetic Origin and Structure

HN is encoded by a 75-bp open reading frame within MT-RNR2. First identified by Hashimoto and colleagues in Alzheimer’s brain tissue, it is 24 residues long (MAPRGFSCLLLLTSEIDLPVKRRA). Nuclear homologs (MTRNR2L loci) share 92–100% sequence similarity, while cross-species orthologs such as rat “rattin” show evolutionary conservation.

Variants and Next-Generation Analogs

Critical residues within the Pro³–Ser¹⁴ domain determine activity. Substitutions at Ser⁷, Cys⁸, Leu⁹, Leu¹², Thr¹³, Ser¹⁴, or Pro¹⁹ abolish function. The S14G substitution yields HNG, >1000-fold more potent. Other analogues include HNGF6A, which enhances insulin secretion, and Colivelin, a hybrid peptide with exceptional neuroprotective potency. Stabilized versions like cyclic D-Ser14 humanin (cHND14) resist degradation and show strong protection in stroke and excitotoxicity models.

Secretion, Trafficking, and Localization

Although lacking a classical signal peptide, HN is secreted via a non-standard route. Key hydrophobic motifs govern this process, enabling export through direct translocation or vesicle pathways. HN first localizes to the mitochondrial matrix before moving into the cytosol and extracellular space. Dimerization enhances its activity, likely by improving receptor binding.

Expression Patterns and Stability

Intracellular HN is regulated by the ubiquitin–proteasome system. TRIM11 targets it for degradation, while proteasome inhibitors stabilize levels. MT-RNR2 transcripts are abundant in metabolically active tissues, and HN peptide is detectable in plasma and cerebrospinal fluid. Levels fall with age, suggesting a link to declining resilience.

Evidence from Animal Studies

Neurodegeneration Models

HN analogs reduced amyloid plaque burden, inflammation, and cognitive deficits in Alzheimer’s mouse models. In stroke models, HNG lowered infarct size by ~50% and synergized with Necrostatin-1 for even greater protection. In Parkinson’s disease models, HN preserved dopaminergic neurons and reduced oxidative stress.

Metabolic and Glucose-Control Findings

HN enhances insulin sensitivity by reducing hepatic glucose output and boosting muscle uptake. Analogues improve glucose tolerance, protect β-cells, and reduce adiposity in diabetic and aging models. Transgenic mice with high HN expression are resistant to insulin resistance, while long-lived dwarf mice naturally have elevated HN.

Cardiovascular Protection

HN protects heart and vasculature during ischemia/reperfusion, reduces infarct size, and improves cardiac function. It also lessens aortic plaque area, preserves endothelial function, and reduces vascular remodeling, highlighting its cardiovascular relevance.

Longevity and Healthspan

HN expression extends lifespan in C. elegans, preserves glucose control and activity in aging mice, and is higher in human centenarians’ offspring. Naked mole rats maintain youthful levels, unlike typical rodents. These findings tie HN to enhanced healthspan and longevity.

Comparative Biology and Synergy

HN is the first member of the mitochondrial-derived peptide (MDP) family, which includes SHLPs and MOTS-c. SHLP2 and SHLP3 promote survival, while SHLP6 has pro-apoptotic roles. MOTS-c complements HN by regulating metabolism via AMPK. Together, these peptides decline with age but rise with exercise and in long-lived models. Combination therapies—such as HN plus Necrostatin-1, or hybrids like Colivelin—outperform HN alone. Regulatory proteins like VSTM2L can antagonize both HN and MOTS-c, highlighting a tightly controlled network.

Conclusions and Future Directions

Humanin represents a paradigm shift in mitochondrial biology. It acts both inside and outside cells to block apoptosis and activate survival pathways, protecting multiple tissues against metabolic, neurodegenerative, and cardiovascular insults. Although context-specific effects and tumor biology raise challenges, the evidence strongly supports HN as a resilience factor. The next steps are improving stability, delivery, and tissue targeting. With optimized analogues or gene-based strategies, HN could emerge as a novel tool to promote healthspan and treat age-related disease.

 

References

Hashimoto Y., Niikura T., Tajima H., et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. Proc Natl Acad Sci USA. 2001;98(11):6336–6341.
Hashimoto Y., Niikura T., Ito Y., et al. Detailed characterization of neuroprotection by a rescue factor Humanin against various Alzheimer’s disease-relevant insults. J Neurosci. 2001;21(23):9235–9245.
Guo B., Zhai D., Cabezas E., et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456–461.
Ikonen M., Liu B., Hashimoto Y., et al. Interaction between the Alzheimer’s survival peptide Humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA. 2003;100(22):13042–13047.
Cobb L.J., Lee C., Xiao J., et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796–809.
Yamagishi Y., Hashimoto Y., Niikura T., Nishimoto I. Identification of essential amino acids in Humanin, a neuroprotective factor against Alzheimer’s disease-relevant insults. Peptides. 2003;24(4):585–595.
Terashita K., Hashimoto Y., Niikura T., et al. Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer’s disease-related neurotoxicity: functional potentiation by isomerization and dimerization. J Neurochem. 2003;85(6):1521–1534.
Muzumdar R.H., Huffman D.M., Calvert J.W., et al. Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. 2010;30(10):1940–1948.
Chiba T., Yamada M., Hashimoto Y., et al. Development of a femtomolar-acting Humanin derivative named colivelin… J Neurosci. 2005;25(52):10252–10261.
Gilon C., Gitlin-Domagalska A., Lazarovici P., et al. Novel Humanin analogs confer neuroprotection… Neuropharmacology. 2020;168:108013.
Wang J., Wang Y., Lin H., et al. Humanin, a mitochondrial-derived peptide, is secreted by astrocytes and improves neuronal energy metabolism. Cell Metab. 2021;33(10):2077–2093.e9.
Niikura T., Kita Y., Abe Y., et al. A tripartite motif protein TRIM11 binds and destabilizes Humanin… Eur J Neurosci. 2003;17(6):1150–1158.
Muzumdar R.H., Huffman D.M., Atzmon G., et al. Humanin: a novel central regulator of peripheral insulin action. PLoS ONE. 2009;4(7):e6334.
Ying G., Iribarren P., Zhou Y., et al. Humanin… uses the G-protein-coupled FPRL1 as a functional receptor. J Exp Med. 2004;199(5):621–627.
Hashimoto Y., Kurita M., Aiso S., Nishimoto I., Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex… Mol Biol Cell. 2009;20(12):2864–2873.
Jia Y., Yang L., Chen Q., et al. Humanin analog protects against germ cell apoptosis… via WSX-1/gp130/STAT3. Cell Death Dis. 2021;12(7):686.
Matsuoka M., Hashimoto Y. Humanin and the receptors for Humanin. Mol Neurobiol. 2010;41(1):22–28.
Ma Z., Liu Z. Humanin decreases mitochondrial membrane permeability by interacting with Bax and Bid. Biochim Biophys Acta. 2018;1859(9):789–801.